Immune Response to SARS-CoV-2 Infections in Children with Secondary Immunodeficiencies.
COVID-19
Cancer
Children
Immunodeficiency
Kidney transplantation
Lymphocyte subsets
SARS-CoV-2
Serology
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
27
07
2022
accepted:
13
09
2022
pubmed:
24
9
2022
medline:
18
1
2023
entrez:
23
9
2022
Statut:
ppublish
Résumé
It is a matter of research, whether children with immunodeficiencies are able to generate an effective immune response to prevent SARS-CoV-2 reinfection. This study aimed to evaluate and compare the seroconversion rates and changes of lymphocyte subsets during COVID-19 in immunocompetent children and those with secondary immunodeficiencies. In 55 children - 28 immunocompromised and 27 immunocompetent - hospitalized with confirmed SARS-CoV-2 infection, the level of IgG antibodies against the Spike protein was determined on two to three occasions. In those children from the study group whose immunosuppressive treatment did not alter during the study (n = 13) and in selected children from the control group (n = 11), flow cytometric evaluation of lymphocyte subsets was performed twice - 2 weeks and 3 months post-infection. Seroconversion reached 96.3% in both studied groups; however, the immunocompromised cohort achieved lower titers of detectable anti-S antibodies. There was no correlation between seroconversion or titers of antibodies and the total number of lymphocytes or their subsets. In the immunocompetent cohort, we reported a significant decrease in NK cells during the infection. In this group and the entire study population, a positive correlation was noticed between the CD4 + /CD8 + T cell ratio and the severity of COVID-19 pneumonia. Children with secondary immunodeficiencies seroconvert in equal percentages but with a significantly lower titer of anti-S antibodies compared to their immunocompetent peers. The lower number of NK cells in the immunocompetent cohort may result from their participation in antiviral immunity, whereas reduced CD4 + /CD8 + T cell ratios among immunocompromised children may be a protective factor against a severe COVID-19.
Sections du résumé
BACKGROUND AND PURPOSE
It is a matter of research, whether children with immunodeficiencies are able to generate an effective immune response to prevent SARS-CoV-2 reinfection. This study aimed to evaluate and compare the seroconversion rates and changes of lymphocyte subsets during COVID-19 in immunocompetent children and those with secondary immunodeficiencies.
METHODS
In 55 children - 28 immunocompromised and 27 immunocompetent - hospitalized with confirmed SARS-CoV-2 infection, the level of IgG antibodies against the Spike protein was determined on two to three occasions. In those children from the study group whose immunosuppressive treatment did not alter during the study (n = 13) and in selected children from the control group (n = 11), flow cytometric evaluation of lymphocyte subsets was performed twice - 2 weeks and 3 months post-infection.
RESULTS
Seroconversion reached 96.3% in both studied groups; however, the immunocompromised cohort achieved lower titers of detectable anti-S antibodies. There was no correlation between seroconversion or titers of antibodies and the total number of lymphocytes or their subsets. In the immunocompetent cohort, we reported a significant decrease in NK cells during the infection. In this group and the entire study population, a positive correlation was noticed between the CD4 + /CD8 + T cell ratio and the severity of COVID-19 pneumonia.
CONCLUSIONS
Children with secondary immunodeficiencies seroconvert in equal percentages but with a significantly lower titer of anti-S antibodies compared to their immunocompetent peers. The lower number of NK cells in the immunocompetent cohort may result from their participation in antiviral immunity, whereas reduced CD4 + /CD8 + T cell ratios among immunocompromised children may be a protective factor against a severe COVID-19.
Identifiants
pubmed: 36149567
doi: 10.1007/s10875-022-01365-8
pii: 10.1007/s10875-022-01365-8
pmc: PMC9510309
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-64Informations de copyright
© 2022. The Author(s).
Références
Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Heal. 2020;4(7):17–8.
doi: 10.1016/S2352-4642(20)30145-0
Hrusak O, Kalina T, Wolf J, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020;132:11–6.
doi: 10.1016/j.ejca.2020.03.021
Węcławek-Tompol J, Zakrzewska Z, Gryniewicz-Kwiatkowska O, et al. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study. J Hematol Oncol. 2021;14(1):163.
doi: 10.1186/s13045-021-01181-4
Canpolat N, Yıldırım ZY, Yıldız N, et al. COVID-19 in pediatric patients undergoing chronic dialysis and kidney transplantation. Eur J Pediatr. 2022;181(1):117–23.
doi: 10.1007/s00431-021-04191-z
Abbott Laboratories. AdviseDx SARS-CoV-2 IgG II – Architect – instructions for use. 2021. Available online: https://www.fda.gov/media/146371/download . Acessed on 6
Piatosa B, Wolska-Kuśnierz B, Siewiera K, Grzduk H, Gałkowska E, Bernatowska E. Distribution of leukocyte and lymphocyte subsets in peripheral blood. Age related normal values for preliminary evaluation of the immune status in Polish children. Centr Eur J Immunol. 2010;35:168–75.
National Institutes of Health. COVID-19 treatment guidelines; Updated the 19
Letizia AG, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712–20.
doi: 10.1016/S2213-2600(21)00158-2
Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11: 610688. https://doi.org/10.3389/fimmu.2020.610688 .
doi: 10.3389/fimmu.2020.610688
Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody responses in COVID-19: a review. Front Immunol. 2021;12: 633184. https://doi.org/10.3389/fimmu.2021.633184 .
doi: 10.3389/fimmu.2021.633184
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12: 698169.
doi: 10.3389/fmicb.2021.698169
Mayanskiy N, Luchkina P, Fedorova N, Lebedin Y, Ponomareva N. Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients. Leukemia. 2021;35(6):1820–2.
doi: 10.1038/s41375-021-01288-0
Müller J, Szűcs-Farkas D, Szegedi I, et al. Clinical course of COVID-19 disease in children treated with neoplastic diseases in Hungary. Pathol Oncol Res. 2022;28:1610261. https://doi.org/10.3389/pore.2022.1610261 .
doi: 10.3389/pore.2022.1610261
Talgam-Horshi E, Mozer-Glassberg Y, Waisbourd-Zinman O, et al. Clinical outcomes and antibody response in COVID-19-positive pediatric solid organ transplant recipients. Pediatr Infect Dis J. 2021;40(12):514–6.
doi: 10.1097/INF.0000000000003293
Alshami A, Al Attas R, Azzam A, Mohammed A, Al-Quhaidan N. Detection of SARS-CoV-2 antibodies in pediatric kidney transplant patients. BMC Nephrol. 2021;22(1):123.
doi: 10.1186/s12882-021-02325-x
Mahmoudi S, Yaghmaei B, Sharifzadeh Ekbatani M, et al. Effects of coronavirus disease 2019 (COVID-19) on peripheral blood lymphocytes and their subsets in children: imbalanced CD4+/CD8+ T cell ratio and disease severity. Front Pediatr. 2021;9: 643299. https://doi.org/10.3389/fped.2021.643299 .
doi: 10.3389/fped.2021.643299
Rogers MC, Williams JV. Quis Custodiet Ipsos Custodes? Regulation of cell-mediated immune responses following viral lung infections. Annu Rev Virol. 2018;5(1):363–83.
doi: 10.1146/annurev-virology-092917-043515
Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. J Infect. 2020;81(1):115–20.
doi: 10.1016/j.jinf.2020.04.001
Lu W, Yang L, Li X, et al. Early immune responses and prognostic factors in children with COVID-19: a single-center retrospective analysis. BMC Pediatr. 2021;21(1):181.
doi: 10.1186/s12887-021-02561-y
Waggoner SN, Reighard SD, Gyurova IE, et al. Roles of natural killer cells in antiviral immunity. Curr Opin Virol. 2016;16:15–23.
doi: 10.1016/j.coviro.2015.10.008
Krämer B, Knoll R, Bonaguro L, et al. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54(11):2650–69.
doi: 10.1016/j.immuni.2021.09.002
Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol. 2020;218: 108516. https://doi.org/10.1016/j.clim.2020.108516 .
doi: 10.1016/j.clim.2020.108516
Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5(50):eabd6832. https://doi.org/10.1126/sciimmunol.abd6832 .
Witkowski M, Tizian C, Ferreira-Gomes M, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600(7888):295–301.
doi: 10.1038/s41586-021-04142-6
Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–7.
doi: 10.1016/j.immuni.2020.04.023
Pan Y, Jiang X, Yang L, et al. SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. Signal Transduct Target Ther. 2021;6(1):256.
doi: 10.1038/s41392-021-00686-1